Company intelligence / Profile preview

Sumocor

New York, NY, USA

Ownership: Private
Development stage: Other

Overview

SumoCor is a biotechnology company focused on developing innovative gene therapies for the treatment of heart failure. The company's core technology centers on the Small Ubiquitin-like Modifier 1 (SUMO1), a protein that regulates the activity of SERCA2a, a calcium pump essential for cardiac muscle contraction. By using adeno-associated virus (AAV) vectors to deliver SUMO1, SumoCor aims to restore cardiac function in patients with failing hearts where SUMO1 levels are typically depleted. Founded by Dr. Roger Hajjar based on research from the Icahn School of Medicine at Mount Sinai, the company was acquired by Asklepios BioPharmaceutical (AskBio) in 2018 to bolster their cardiovascular pipeline.

Therapeutic areas: Cardiovascular
Modalities: Gene therapyAAV vector
Industry: Biotech

Partnerships

Mount Sinai Health System

Beyond the preview

Go deeper on Sumocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumocor.

Explore the full profile